Effect of efflux pump inhibitors on the susceptibility of Mycobacterium avium complex to clarithromycin.
Journal
The Journal of antibiotics
ISSN: 1881-1469
Titre abrégé: J Antibiot (Tokyo)
Pays: England
ID NLM: 0151115
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
18
06
2019
accepted:
04
09
2019
revised:
02
09
2019
pubmed:
19
10
2019
medline:
9
9
2020
entrez:
19
10
2019
Statut:
ppublish
Résumé
In this study we aimed to evaluate the effect of the combination of clarithromycin and four inhibitors of efflux pumps (EPIs), including berberine (BER), carbonyl cyanide m-chlorophenylhydrazone (CCCP), piperine (PIP) and tetrandrine (TET), against 12 Mycobacterium avium complex clinical isolates. The minimum inhibitory concentration (MIC) of clarithromycin showed at least a fourfold reduction in presence of BER (83% of total isolates), CCCP (67%), PIP (25%) and TET (75%). Our results showed that the EPIs tested are active against both clarithromycin susceptible and resistant isolates. In particular, among the six resistant isolates, TET reversed the resistance phenotype of three strains, BER of two strains, and CCCP and PIP of one strain. Overall, our findings show the importance of these compounds in increasing the efficacy of clarithromycin in MAC clinical isolates.
Identifiants
pubmed: 31624335
doi: 10.1038/s41429-019-0245-1
pii: 10.1038/s41429-019-0245-1
doi:
Substances chimiques
Anti-Bacterial Agents
0
Membrane Transport Proteins
0
Clarithromycin
H1250JIK0A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-132Références
Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36:13–34.
doi: 10.1016/j.ccm.2014.10.002
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.
doi: 10.1164/rccm.200604-571ST
van Ingen J, Turenne CY, Tortoli E, Wallace RJ Jr, Brown-Elliott BA. A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review. Int J Syst Evol Microbiol. 2018;68:3666–77.
doi: 10.1099/ijsem.0.003026
Han XY1, Tarrand JJ, Infante R, Jacobson KL, Truong M. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol. 2005;43:4407–12.
doi: 10.1128/JCM.43.9.4407-4412.2005
Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis. 2012;25:218–27.
doi: 10.1097/QCO.0b013e3283511a64
Doucet-Populaire F, Buriankova K, Weiser J, Pernodet JL. Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord. 2002;2:355–70.
doi: 10.2174/1568005023342263
Nasiri MJ, Haeili M, Ghazi M, Goudarzi H, Pormohammad A, Imani Fooladi AA, et al. New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria. Front Microbiol. 2017;8:681.
doi: 10.3389/fmicb.2017.00681
Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother. 2012;56:4806–15.
doi: 10.1128/AAC.05546-11
Song LL, Wu XQ. Development of efflux pump inhibitors in antituberculosis therapy. Int J Antimicrob Agents. 2016;47:421–29.
doi: 10.1016/j.ijantimicag.2016.04.007
Cannalire R, Machado D, Felicetti T, Santos Costa S, Massari S, Manfroni G, et al. Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. Eur J Med Chem. 2017;140:321–30.
doi: 10.1016/j.ejmech.2017.09.014
Deshpande D, Srivastava S, Musuka S, Gumbo T. Thioridazine as chemotherapy for Mycobacterium avium complex diseases. Antimicrob Agents Chemother. 2016;60:4652–8.
doi: 10.1128/AAC.02985-15
Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, Amaral L, et al. The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int J Antimicrob Agents. 2009;34:529–33.
doi: 10.1016/j.ijantimicag.2009.07.010
Shin SJ, Lee BS, Koh WJ, Manning EJ, Anklam K, Sreevatsan S, et al. Efficient differentiation of Mycobacterium avium complex species and subspecies by use of five-target multiplex PCR. J Clin Microbiol. 2010;48:4057–62.
doi: 10.1128/JCM.00904-10
Palomino J-C, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2002;46:2720–2.
doi: 10.1128/AAC.46.8.2720-2722.2002
Jamal MA, Maeda S, Nakata N, Kai M, Fukuchi K, Kashiwabara Y. Molecular basis of clarithromycin-resistance in Mycobacterium avium-intracellulare complex. Tube Lung Dis. 2000;80:1–4.
doi: 10.1054/tuld.1999.0227
Clinical and Laboratory Standards Institute. Susceptibility testing for Mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standard M24-A. Clinical and Laboratory standards Institute, Wayne, PA. 2011.
Zhou XY, Ye XG, He LT, Zhang SR, Wang RL, Zhou J, et al. In vitro characterization and inhibition of the interaction between ciprofloxacin and berberine against multidrug-resistant Klebsiella pneumoniae. J Antibiot. 2016;69:741–6.
doi: 10.1038/ja.2016.15
Morita Y, Nakashima K, Nishino K, Kotani K, Tomida J, Inoue M, et al. Berberine is a novel type efflux inhibitor which attenuates the MexXY-mediated aminoglycoside resistance in Pseudomonas aeruginosa. Front Microbiol. 2016;7:1223.
doi: 10.3389/fmicb.2016.01223
Hegeto LA, Caleffi-Ferracioli KR, Nakamura-Vasconcelos SS, Almeida AL, Baldin VP, Nakamura CV, et al. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis. Tuberculosis. 2018;111:35–40.
doi: 10.1016/j.tube.2018.05.006
Zhang Z, Yan J, Xu K, Ji Z, Li L. Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates. BMC Infect Dis. 2015;15:153.
doi: 10.1186/s12879-015-0905-0